Treatment of pulmonary embolism with positive end-expiratory pressure and prostaglandin E1.
D015121:6-Ketoprostaglandin F1 alpha; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D004285:Dogs; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D011175:Positive-Pressure Respiration; D011458:Prostaglandins E / Q000627:therapeutic use*; D011460:Prostaglandins F / Q000097:blood; D011651:Pulmonary Artery; D011655:Pulmonary Embolism / Q000628:therapy*; D013929:Thromboxane B2 / Q000097:blood
D005338:Fibrin Fibrinogen Degradation Products; D011458:Prostaglandins E; D011460:Prostaglandins F; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha